Back
Full-text
Journal article

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

  • Yatabe Y Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. Electronic address: yyatabi@aichi-cc.jp.
  • Dacic S Department of Pathology University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Borczuk AC Department of Pathology, Weill Cornell Medicine, New York, New York.
  • Warth A Institute of Pathology, Cytopathology, and Molecular Pathology MVZ UEGP Giessen, Wetzlar, Limburg, Germany.
  • Russell PA Anatomical Pathology Department, St. Vincent's Hospital and the University of Melbourne, Fitzroy, Victoria, Australia.
  • Lantuejoul S Department of Biopathology, Centre Léon Bérard, Grenoble Alpes University, Lyon, France.
  • Beasley MB Department of Pathology, Mount Sinai Medical Center, New York, New York.
  • Thunnissen E Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
  • Pelosi G Department of Oncology and Hemato-Oncology, University of Milan and IRCCS MultiMedica, Milan, Italy.
  • Rekhtman N Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bubendorf L Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Mino-Kenudson M Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Yoshida A Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
  • Geisinger KR Department of Pathology, The University of Mississippi Medical Center, Jackson, Mississippi.
  • Noguchi M Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Japan.
  • Chirieac LR Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Bolting J Department of Immunology Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Chung JH Department of Pathology and Respiratory Center, Seoul National University Bundang Hospital, Seongnam city, Gyeonggi- do, Republic of Korea.
  • Chou TY Division of Molecular Pathology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Republic of China.
  • Chen G Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Poleri C Office of Pathology Consultants, Buenos Aires, Argentina.
  • Lopez-Rios F Laboratorio de Dianas Terapeuticas, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Papotti M Department of Oncology, University of Turin, Turin, Italy.
  • Sholl LM Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Roden AC Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Minnesota.
  • Travis WD Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hirsch FR University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Kerr KM Department of Pathology, Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, Scotland, United Kingdom.
  • Tsao MS Department of Pathology, University Health Network/Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Nicholson AG Department of Histopathology, Royal Brompton and Harefield National Health Service Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Wistuba I Department of Translational Molecular Pathology, M. D. Anderson Cancer Center, Houston, Texas.
  • Moreira AL Department of Pathology, New York University Langone Health, New York, New York.
Show more…
  • 2018-12-21
Published in:
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. - 2019
Immunohistochemistry
Lung cancer
Neuroendocrine markers
TTF1
p40
Antibodies, Monoclonal
Biomarkers, Tumor
Diagnosis, Differential
Early Detection of Cancer
Humans
Immunohistochemistry
Lung Neoplasms
Practice Guidelines as Topic
Prognosis
English Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non-small cell carcinoma, patients' treatment of choice is directly linked to histologic subtypes of non-small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/111250
Statistics
Document views: 151 File downloads:
  • Full-text: 0